China Approves World's First Functional Cure Drug for Hepatitis B
核心洞察
China has approved Pegbing (搜索), the world's first domestically developed drug designed to achieve a functional cure for hepatitis B (搜索), developed by Amoytop Biotech (搜索) in Xiamen.
The injectable drug is approved for combination use with antiviral medication to achieve sustained clearance of hepatitis B surface antigen in adults with chronic hepatitis B (搜索).
Clinical trial data shows 31.4 percent of patients receiving combination therapy achieved clinical cure 24 weeks after discontinuing all medications, significantly higher than conventional treatments.
China's National Medical Products Administration (搜索) has approved Pegbing (搜索), marking the world's first market authorization for a drug specifically designed to achieve a functional cure for hepatitis B (搜索). The injectable therapy, developed by Amoytop Biotech (搜索) based in Xiamen, Fujian province, represents a significant breakthrough in treating the chronic liver infection that affects millions globally.
Regulatory Milestone and Global Impact
The approval allows Pegbing (搜索) to be used in combination with antiviral medication to achieve sustained clearance of the hepatitis B surface antigen in adults with chronic hepatitis B (搜索). According to the Chinese Foundation for Hepatitis Prevention and Control (搜索), this represents the world's first market authorization for a drug aimed at achieving functional cure for hepatitis B (搜索), ushering in a new stage in the global battle against the viral infection.
The significance of this development becomes clear when considering the global disease burden. Hepatitis B (搜索) affects approximately 254 million people worldwide and causes more than 1 million related deaths each year. China alone has about 75 million chronic hepatitis B (搜索) patients, making this approval particularly impactful for the domestic healthcare system.
Defining Functional Cure
A functional cure for hepatitis B (搜索) is defined as the sustained loss of the hepatitis B surface antigen after treatment cessation. This approach differs fundamentally from conventional therapies that suppress viral replication but do not eliminate the virus entirely. The distinction is crucial for patient outcomes and long-term prognosis.
Data from the Chinese Foundation for Hepatitis Prevention and Control (搜索) reveals the clinical importance of achieving functional cure. More than 92 percent of liver cancer (搜索) cases in China are caused by hepatitis B (搜索) infection. The incidence of liver cancer can be reduced to 10.7 percent among patients receiving antiviral treatment, compared with nearly 15 percent among those who do not receive treatment. For patients who achieve clinical cure, the rate drops dramatically to just 1 percent.
"Such a significant difference underscores the critical importance of achieving clinical cure for hepatitis B (搜索) patients," the foundation stated.
Clinical Trial Results
Amoytop Biotech (搜索) reported promising results from clinical trials evaluating the efficacy and safety of Pegbing (搜索) in combination with antiviral treatment. In the study, 31.4 percent of patients receiving the combination therapy achieved clinical cure 24 weeks after discontinuing all medications. This rate represents a significant improvement over conventional treatment regimens.
The clinical trial data supports the drug's potential to transform hepatitis B (搜索) treatment by offering patients the possibility of sustained viral clearance rather than lifelong suppression therapy.
National Treatment Goals
The approval aligns with China's broader public health objectives for hepatitis B (搜索) management. According to an action plan released by the National Disease Control and Prevention Administration and eight other government departments, China aims to raise the antiviral treatment rate for newly reported cases to at least 80 percent by 2030.
The plan emphasizes intensified efforts in innovative drug research and development and the exploration of new solutions for the functional cure of hepatitis B (搜索). Pegbing (搜索)'s approval represents a concrete step toward achieving these ambitious treatment targets and potentially reducing the substantial disease burden associated with chronic hepatitis B (搜索) infection in China and globally.